Education
About Us
Working with TipRanks
Follow Us
Vaxxinity Inc (VAXX)
OTHER OTC:VAXX
VAXX Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.09
Previous CloseN/A
Volume1.04K
Average Volume (3M)4.32K
Market Cap
$140.66K
Enterprise ValueN/A
Total Cash (Recent Filing)$30.39M
Total Debt (Recent Filing)$15.17M
Price to Earnings (P/E)―
Beta66.58
Next Earnings
Apr 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding126,784,680
10 Day Avg. Volume198
30 Day Avg. Volume4,323
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Vaxxinity Inc News
VAXX FAQ
What was Vaxxinity Inc’s price range in the past 12 months?
Vaxxinity Inc lowest stock price was <$0.01 and its highest was $0.09 in the past 12 months.
What is Vaxxinity Inc’s market cap?
Vaxxinity Inc’s market cap is $140.66K.
When is Vaxxinity Inc’s upcoming earnings report date?
Vaxxinity Inc’s upcoming earnings report date is Apr 01, 2025 which is 170 days ago.
How were Vaxxinity Inc’s earnings last quarter?
Currently, no data Available
Is Vaxxinity Inc overvalued?
According to Wall Street analysts Vaxxinity Inc’s price is currently Overvalued.
Does Vaxxinity Inc pay dividends?
Vaxxinity Inc does not currently pay dividends.
What is Vaxxinity Inc’s EPS estimate?
Vaxxinity Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxxinity Inc have?
Vaxxinity Inc has 126,784,680 shares outstanding.
What happened to Vaxxinity Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaxxinity Inc?
Currently, no hedge funds are holding shares in VAXX
Company Description
Vaxxinity Inc
Vaxxinity Inc (VAXX) is a biotechnology company focused on the development of vaccines and therapeutics for the treatment of chronic diseases. The company leverages its proprietary synthetic peptide vaccine platform to create a new class of medicines aimed at transforming the treatment landscape for neurodegenerative diseases, infectious diseases, and other chronic illnesses. Vaxxinity's core products are designed to harness the body's immune response to target and manage disease progression.
Vaxxinity Inc (VAXX) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Matinas BioPharma
―
Scinai Immunotherapeutics
―
Quoin Pharmaceuticals
―
Aptevo Therapeutics
―
Galecto
―
Ownership Overview
79.90%
Insiders
0.06% Mutual Funds
0.02% Other Institutional Investors
99.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---